Spero In-Licenses Phase 2-Ready Anti-CD40L Antibody SP001 and Secures $105M Non-Dilutive Royalty Financing, Extending Cash Runway into 2H 2029
SPRO sits 17% above its 52-week low of $1.8.
Summary
Spero Therapeutics in-licensed SP001, a Phase 2-ready anti-CD40L antibody, from Innovent for $35M upfront and up to $1.05B in milestones, and secured $105M in non-dilutive royalty financing backed by Utebzi, extending cash runway into 2H 2029.
Key Events · M&A and Partnerships · SPRO
-
SP001 License Agreement
Spero obtained exclusive global rights (ex-Greater China) to SP001, a Phase 2-ready anti-CD40L antibody, from Innovent. Upfront payment of $35M, with up to ~$1.05B in development, regulatory, and commercial milestones, plus tiered royalties on net sales.
-
$105M Royalty Financing
Spero closed a $105M non-recourse royalty financing with HCRx, secured by future Utebzi milestones and royalties from GSK. The deal includes senior secured notes at 10% interest and sale of 65% of residual GSK proceeds for $1.575M, providing non-dilutive capital.
-
Cash Runway Extended to 2H 2029
Proceeds from the royalty financing, combined with existing cash, are expected to fund operations into the second half of 2029, supporting SP001 Phase 2 development and other corporate activities.
-
Pipeline Pivot to Immunology
SP001 becomes Spero's lead immunology asset, with a Phase 2 trial in IgG4-related disease planned for Q2 2027. The antibody has completed Phase 1 studies in healthy volunteers and Sjögren's disease, showing favorable safety and efficacy signals.
Analysis · SPRO · Life Sciences
Spero Therapeutics announced two transformative deals: an exclusive global license (ex-Greater China) for SP001, a Phase 2-ready anti-CD40L antibody from Innovent, and a $105 million non-recourse royalty financing backed by future Utebzi milestones and royalties. The SP001 deal reshapes Spero's pipeline into immunology, with a Phase 2 trial in IgG4-related disease planned for Q2 2027. The financing, structured as senior secured notes and a sale of 65% of residual GSK proceeds, provides non-dilutive capital to fund SP001 development and extends cash runway into the second half of 2029. Together, these moves pivot the company from infectious disease to immunology while strengthening its balance sheet without shareholder dilution.
At the time of this filing, SPRO was trading at $2.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $126.2M. The 52-week trading range was $1.80 to $3.08. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.